Percentages of primary CD45.2 donor cells engrafted in a secondary recipient mouse after transplantation of murine ST-HSCs CD34+ HSCs cells treated with or without the rhFTVI
| Experiment, n . | Cell*/treatment . | Treatment . | Mice, n . | Percentage of Donor Cells in Recipient Mice (w), % . | |||
|---|---|---|---|---|---|---|---|
| 2 w . | 4 w . | 8 w . | 12 w . | ||||
| 1 | Flk2−CD34+ | HBSS | 5 | 0, 0, 0, 0.2 | 0, 0, 0, 0.4, 0.4 | 0, 0, 0, 0.4, 0.4 | 0, 0, 0, 0, 0 |
| Flk2−CD34+ | rhFTVI | 5 | 6.8, 13.4, 6.3, 2.0, 3.2 | 2.7, 0.6, 1.2, 0.5, 3.0 | 0.5, 0.8, 1.2, 1.4, 11.3 | 2.7, 0, 15, 15.2, 0.2 | |
| 2 | Flk2−CD34+ | HBSS | 10 | 0, 0, 0, 0, 0.2, 0.2, 0, 0, 0, 0, | 0, 0, 0, 0, 0.2, 0.2, 0, 0, 0, 0, | 0, 0, 0, 0.3, 0, 0.2, 0, 0, 0, 0, | |
| Flk2−CD34+ | rhFTVI | 9 | 0.5, 8.0, 1.6, 1.1, 2.3, 0.4, 2.2, 0.2, 1.0 | 0.5, 8.0, 1.6, 1.1, 2.3, 0.4, 2.2, 0.2, 1.0 | 1.3, 0.2, 10, 2.4, 1.6, 6.8, 1, 1.1, 1 | ||
| Experiment, n . | Cell*/treatment . | Treatment . | Mice, n . | Percentage of Donor Cells in Recipient Mice (w), % . | |||
|---|---|---|---|---|---|---|---|
| 2 w . | 4 w . | 8 w . | 12 w . | ||||
| 1 | Flk2−CD34+ | HBSS | 5 | 0, 0, 0, 0.2 | 0, 0, 0, 0.4, 0.4 | 0, 0, 0, 0.4, 0.4 | 0, 0, 0, 0, 0 |
| Flk2−CD34+ | rhFTVI | 5 | 6.8, 13.4, 6.3, 2.0, 3.2 | 2.7, 0.6, 1.2, 0.5, 3.0 | 0.5, 0.8, 1.2, 1.4, 11.3 | 2.7, 0, 15, 15.2, 0.2 | |
| 2 | Flk2−CD34+ | HBSS | 10 | 0, 0, 0, 0, 0.2, 0.2, 0, 0, 0, 0, | 0, 0, 0, 0, 0.2, 0.2, 0, 0, 0, 0, | 0, 0, 0, 0.3, 0, 0.2, 0, 0, 0, 0, | |
| Flk2−CD34+ | rhFTVI | 9 | 0.5, 8.0, 1.6, 1.1, 2.3, 0.4, 2.2, 0.2, 1.0 | 0.5, 8.0, 1.6, 1.1, 2.3, 0.4, 2.2, 0.2, 1.0 | 1.3, 0.2, 10, 2.4, 1.6, 6.8, 1, 1.1, 1 | ||
cell number = Experiment 1 was ∼800 to 1000, and Experiment 2 was ∼300 to 800.